Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2009 Jul;14(13-14):690-7. doi: 10.1016/j.drudis.2009.05.002. Epub 2009 May 19.

Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.

Author information

1
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, United States. john.krystal@yale.edu

Abstract

Current treatments for psychiatric disorders were developed with the aim of providing symptomatic relief rather than reversing underlying abnormalities in neuroplasticity or neurodevelopment that might contribute to psychiatric disorders. This review considers the possibility that psychiatric treatments might be developed that target neuroplasticity deficits or that manipulate neuroplasticity in novel ways. These treatments might not provide direct symptomatic relief. However, they might complement or enhance current pharmacotherapies and psychotherapies aimed at the prevention and treatment of psychiatric disorders. In considering neuroplasticity as a target for the treatment of psychiatric disorders, we build on exciting new findings in the areas of anxiety disorders, mood disorders, and schizophrenia.

PMID:
19460458
PMCID:
PMC2898127
DOI:
10.1016/j.drudis.2009.05.002
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center